Harpoon Therapeutics, Inc.
HARPDelisted Mar 11, 2024- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001708493
Harpoon Therapeutics, Inc. was delisted on Mar 11, 2024; its insiders filed their last Form 4 on Mar 11, 2024; 41 institutions reported holding it in 13F filings for Q4 2023, worth $175.5M in total; no superinvestor held it.
Q3 2022 vs. Q2 2022
How the institutions holding Harpoon Therapeutics, Inc. changed between Q2 2022 and Q3 2022.
All holders in Q3 2022All holders in Q2 2022
| Measure | Q2 2022 | Q3 2022 | Change |
|---|---|---|---|
| Holders | 63 | 52 | −11 |
| Shares | 22.7M | 21.7M | −1.04M (−4.6%) |
| Value | $43.4M | $21.0M | −$22.4M (−51.5%) |
New holders (3)
Institutions that held Harpoon Therapeutics, Inc. at the end of Q3 2022 but not at the end of Q2 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Piper Sandler & Co. | 580,815 | $563.0K | 0.46% |
| Gsa Capital Partners LLP | 109,136 | $106.0K | 0.01% |
| China Universal Asset Management Co., Ltd. | 310 | $0 | 0.00% |
Sold out (14)
Institutions that held Harpoon Therapeutics, Inc. at the end of Q2 2022 and filed for Q3 2022 without it.
| Institution | Shares, Q2 2022 | Value, Q2 2022 |
|---|---|---|
| Point72 Asset Management, L.P. | 870,700 | $1.66M |
| Jacobs Levy Equity Management, Inc | 329,842 | $630.0K |
| Schonfeld Strategic Advisors LLC | 240,221 | $458.0K |
| Citadel Advisors LLC | 129,396 | $247.0K |
| Marshall Wace, LLP | 71,743 | $137.0K |
| Susquehanna International Group, LLP | 40,223 | $77.0K |
| D. E. Shaw & Co., Inc. | 18,730 | $36.0K |
| Sequoia Financial Advisors, LLC | 16,200 | $31.0K |
| Charles Schwab Investment Management Inc | 10,228 | $20.0K |
| HRT Financial LP | 10,777 | $20.0K |
| Cubist Systematic Strategies, LLC | 3,214 | $6.00K |
| Spire Wealth Management | 1,000 | $2.00K |
| New York State Common Retirement Fund | 156 | $0 |
| Credit Suisse AG | 10 | $0 |